The State of Content Marketing for Pharma 2026
What does good pharma content marketing actually look like?
The small cohort of pharma companies that takes content seriously has the structural basics solved and the strategic layer mostly unbuilt. About 9 in 10 active-cohort sites use clean headings, contextual CTAs, and regulatory content, but only about 9 in 20 run funnel-segmented CTAs, and only 3 in 10 publish original research.
Why download this
- Read the bar that defines best practice inside the active cohort
- Spot the strategic gaps competitors have not closed
- Set a priority list against a real benchmark, not a generic checklist
What the data shows
- About 9 in 10 active-cohort sites use clean heading structures and contextual CTAs
- Only about 9 in 20 run funnel-segmented CTAs. The other 55 percent ask every reader the same thing
- About 3 in 10 publish original research or proprietary data, the most defensible content asset in pharma
- About 1 in 8 include Key Takeaways or FAQ sections, the formats that drive time on page and featured snippets
- About 0 percent point paid search ads at content assets
How to use it
- Audit your CTAs by funnel stage before producing anything new
- Commit to one piece of original research per quarter and build the methodology before the content
- Connect paid search budget to your highest-converting content assets, not just service pages